Key Figures (in EUR thousand)

• Revenue: 466 in Q3 2007, down by 61% (Q3 2006: 1,203)
• EBIT: -3,229 in Q3 2007, improved by 15% (Q3 2006: -3,790)
• Net loss: -3,139 in Q3 2007, improved by 16% (Q3 2006: -3,740)
• Liquid assets: 13,024 as of 30/09/2007 (31/12/2006: 17,341)

Highlights of the Third Quarter 2007

• Strategic in-vitro diagnostics partnership with Abbott Molecular signed
• Continued successful execution of revised strategy
• Medical Advisory Board for colorectal cancer screening development program established
• Numerous new candidate biomarkers within prostate cancer screening program identified
• All development programs on track and in line with expectations
• Key patents for early cancer detection technology granted
• Biomarker R&D partnership with pharmaceutical partner expanded
• All key financials for first nine months 2007 within expectations: Operating costs reduced, EBIT improved

Berlin, Germany and Seattle, WA, USA,

Entire workflow of Epigenomics’ diagnostic tests now protected

Press Release, Berlin, Germany, and Seattle, WA, U.S.A.

Collaboration focuses on development and global commercialization of a molecular diagnostic test for the early detection of colorectal cancer

• Abbott obtains non-exclusive worldwide rights to Epigenomics’ proprietary DNA methylation biomarker Septin 9
• Anticipate European market launch in 2009; filing for U.S. approval in 2010
• Epigenomics to receive an up-front fee, milestone payments and royalties
• Option to expand partnership on multiple Epigenomics biomarkers to other cancer indications

Ad hoc (§15 WpHG) Berlin, Germany, and Seattle, WA, USA,

Latest data on utility of DNA methylation biomarkers for early detection and diagnosis of prostate cancer to be presented at two high profile European conferences

Press Release, Berlin, Germany, and Seattle, WA, USA

• Technical study met its objectives
• Considerable improvements in simplicity, processing time, costs, and automation potential
• Epigenomics most advanced program, a colorectal cancer screening test, now ready for planned reference laboratory transfer 
• Basis for future IVD test kit development together with diagnostic industry partners

Press Release, Berlin, Germany and Seattle, WA, U.S.A. 
 

• Positive clinical data from collaborative study with Charité
• Potential to address a high unmet medical need as no IVD test for lung cancer available thus far
• Successful clinical proof-of-concept in third cancer screening test development program
• Further step towards building an early cancer detection franchise with diagnostic industry partners

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

QIAGEN acquires exclusive world wide license to Epigenomics’ preanalytical DNA-Methylation Technology for use in Molecular Diagnostics

Press Release, Berlin, Germany and Venlo, The Netherlands

Prof. Dr. Matthias Ebert Presented Data at Digestive Disease Week 2007

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

• Key financials within expectations and guidance
• All tactical and strategic financing options under assessment
• Geert Walther Nygaard appointed new CEO
• Heino von Prondzynski nominated for election to Supervisory Board at next AGM
• Realinged strategy with stronger focus on fast commercialization of colorectal cancer screening product

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

Epigenomics AG presented most recent data at AACR Annual Meeting 2007

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

Epigenomics AG gives detailed account of research into optimized assay procedure for early cancer detection at CHI’s G.O.T. Summit

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

Focus on early detection of colorectal cancer – New Strategy aims at fastest route to market and commercialization

• Financials in line with latest expectations:
• Full year revenue EUR 3.5 million, EBIT at EUR -15.8 million
• Operational costs EUR 21.2 million
• Liquidity of EUR 17.3 million as of December 31 2006
• Dedicated project evaluating all strategic and tactical financing options started in Q4-2006
• Strategy and organization realigned with focus on key value drivers and fastest route to market
• Positive clinical data from colorectal and prostate cancer screening programs
• Roche Diagnostics ended partnership despite positive clinical data – all rights reverted to Epigenomics
• Qiagen launched EpiTect ® Bisulfite Kit for research use
• Affymetrix became strategic diagnostics platform partner and shareholder
• Seven new biomarker R&D collaborations
• New CEO Geert Nygaard joined early 2007 to succeed founder Alex Olek